Skip to main content
. 1999 May 11;96(10):5710–5715. doi: 10.1073/pnas.96.10.5710

Table 1.

Flow cytometry on sera from 18 patients

Patient no. Dose level μg % positive cells
IgM
IgG
Pre- Post- Pre- Post-
1 1 10 9.6 12.8 9.1 9.9
2 1 10 10.9 30.7 10.1 10.8
3 1 10 9.9 25.2 9.2 4.9
4 1 10 10.8 26.4 12.7 10.4
6 2 30 10.8 52.2 10.5 10.4
7 2 30 9.0 11.2 10.5 10.3
8 2 30 10.5 96.9 9.5 34.9
9 2 30 11.1 47.5 11.7 33.3
10 2 30 9.5 16.3 9.7 14.2
11 3 100 10.5 23.2 10.4 8.2
12 3 100 9.9 32.4 10.1 13.5
13 3 100 10.9 63.0 9.2 12.9
14 3 100 10.6 19.8 9.4 15.9
15 3 100 9.6 33.6 11.4 12.7
16 4 3 11.4 19.9 10.6 5.9
17 4 3 9.9 4.7 9.9 13.2
18 4 3 9.1 7.1 10.3 2.2
19 4 3 8.5 8.9 11.3 6.3
MBr1 mAb 64.7
VK-9 mAb 62.1
Unstained 0.9 1.7

Patients’ pre- and post-treatment sera were incubated with MCF-7 cells and then with FITC-conjugated anti-human IgM or IgG antibody. The percent fluorescent cells incubated with pretreatment sera were gated to have values of approximately 10% and were compared with posttreatment values. Positive controls included anti-globo H mAb VK9. Patient 5 was taken out of the study because of overwhelming infection. Patient 20 was taken out because of rapid progression of disease.